
Aytu BioPharma: A global specialty healthcare firm focusing on urological disorders and male infertility.
Founded with a mission to improve patient health globally, Aytu BioPharma, Inc. is a specialty healthcare company that focuses on acquiring, developing, and commercializing innovative products for complex conditions. The company's core areas of expertise include sexual dysfunction disorders, urological cancer, urinary tract infections, male infertility, and ADHD. Aytu BioPharma aims to enhance patient wellness through a diverse portfolio of prescription therapeutics designed to help patients lead healthier and more fulfilling lives.
Aytu BioPharma has garnered attention for its impactful contributions to healthcare, supported by a team of dedicated professionals and strategic investors. The company has achieved significant milestones in advancing treatments for ADHD and urological disorders, reflecting its commitment to addressing unmet medical needs. Through its innovative therapies and global reach, Aytu BioPharma continues to make a substantial impact on patient care and the broader healthcare landscape.

UroGen Pharma
urogen.com
Apricus Biosciences
apricusbio.com

BioCryst Pharmaceuticals
biocryst.com

Arbutus Biopharma
arbutusbio.com

Aptinyx
aptinyx.com

Anthera Pharmaceuticals
anthera.com

Aquavit Pharmaceuticals
aquavitpharma.com

Superior Biologics

aTyr Pharma
atyrpharma.com

Woolsey Pharmaceuticals
woolseypharma.com

Marius Pharmaceuticals
mariuspharma.com

AltaThera Pharmaceuticals
altathera.com

PTC Therapeutics
ptcbio.com
Aya Biosciences
bioaya.com

Attune Pharmaceuticals

Boston Biopharma

Assertio Holdings

Avalyn Pharma
avalynpharma.com

Innoviva
inva.com

Integrated BioPharma
ibiopharma.com
Companies similar to Aytu BioPharma include UroGen Pharma, Apricus Biosciences, BioCryst Pharmaceuticals and Arbutus Biopharma.
Aytu BioPharma was founded in 2015.
Aytu BioPharma's headquarters is located in Denver, CO, US.
Aytu BioPharma's most recent funding round was for $4M (USD) in June 2023.
As of Jun 9, 2023, Aytu BioPharma has disclosed funding of $36M (USD).
Aytu BioPharma has 164 employees as of Feb 6, 2024.